Clinical and Radiological Features of Korean Patients With Anti-HMGCR Myopathy
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background and Purpose To understand the characteristics of Korean patients with anti- 3-hydroxy-3-methylglutaryl-coenxyme A reductase (HMGCR) myopathy, we measured anti- HMGCR antibodies and analyzed the clinical, radiological, and pathological features of patients with anti-HMGCR myopathy. Methods We measured titers of anti-HMGCR antibodies in the sera of 99 patients with inflammatory myopathy, 36 patients with genetic myopathy, and 63 healthy subjects using an enzyme-linked immunosorbent assay. We tested 16 myositis-specific autoantibodies (MSAs) in all patients with anti-HMGCR myopathy. Results Positivity for the anti-HMGCR antibody was observed in 17 (4 males and 13 females) of 99 patients with inflammatory myopathy. The median age at symptom onset was 60 years. Ten (59%) of the patients with anti-HMGCR positivity had taken statins. The titer of anti- HMGCR antibodies was significantly higher in the statin-naïve group (median=230 U/mL, interquartile range=170–443 U/mL) than in the statin-exposed group (median=178 U/mL, interquartile range=105–210 U/mL, p=0.045). The most common symptom was proximal muscle weakness in 15 patients (88%), followed by myalgia in 9 (53%), neck weakness in 4 (24%), dysphagia in 3 (18%), and skin lesions in 2 (12%). The median titer of anti-HMGCR antibody was 202 U/mL. We found eight different MSAs in nine (53%) patients. The median disease duration from symptom onset to diagnosis was significantly shorter in the MSA-positive group than in the MSA-negative group (p=0.027). Conclusions Our study was the first to measure anti-HMGCR antibodies in inflammatory myopathy. It has provided new findings, including the suggestion of the coexistence of other MSAs in Korean patients.
Abstract
Background and Purpose To understand the characteristics of Korean patients with anti- 3-hydroxy-3-methylglutaryl-coenxyme A reductase (HMGCR) myopathy, we measured anti- HMGCR antibodies and analyzed the clinical, radiological, and pathological features of patients with anti-HMGCR myopathy. Methods We measured titers of anti-HMGCR antibodies in the sera of 99 patients with inflammatory myopathy, 36 patients with genetic myopathy, and 63 healthy subjects using an enzyme-linked immunosorbent assay. We tested 16 myositis-specific autoantibodies (MSAs) in all patients with anti-HMGCR myopathy. Results Positivity for the anti-HMGCR antibody was observed in 17 (4 males and 13 females) of 99 patients with inflammatory myopathy. The median age at symptom onset was 60 years. Ten (59%) of the patients with anti-HMGCR positivity had taken statins. The titer of anti- HMGCR antibodies was significantly higher in the statin-naïve group (median=230 U/mL, interquartile range=170–443 U/mL) than in the statin-exposed group (median=178 U/mL, interquartile range=105–210 U/mL, p=0.045). The most common symptom was proximal muscle weakness in 15 patients (88%), followed by myalgia in 9 (53%), neck weakness in 4 (24%), dysphagia in 3 (18%), and skin lesions in 2 (12%). The median titer of anti-HMGCR antibody was 202 U/mL. We found eight different MSAs in nine (53%) patients. The median disease duration from symptom onset to diagnosis was significantly shorter in the MSA-positive group than in the MSA-negative group (p=0.027). Conclusions Our study was the first to measure anti-HMGCR antibodies in inflammatory myopathy. It has provided new findings, including the suggestion of the coexistence of other MSAs in Korean patients.
참고문헌 (31)
- Christopher-Stine L, "A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy", Arthritis Rheum, 62, pp.2757~2766 (2010)
- Targoff IN, "Antibody to signal recognition particle in polymyositis", Arthritis Rheum, 33, pp.1361~1370 (1990)
- van der Most PJ, "Statins : mechanisms of neuroprotection", Prog Neurobiol, 88, pp.64~75 (2009)
- Mammen AL, "Autoantibodies against 3-hydroxy-3-methylglutarylcoenzyme A reductase in patients with statin-associated autoimmune myopathy", Arthritis Rheum, 63, pp.713~721 (2011)
- Limaye V, "Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy", Muscle Nerve, 52, pp.196~203 (2015)
- Klein M, "Increasing incidence of immune-mediated necrotizing myopathy:single-centre experience", Rheumatology(Oxford), 54, pp.2010~2014 (2015)
- Watanabe Y, "Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy", J Neurol Neurosurg Psychiatry, 87, pp.1038~1044 (2016)
- Mammen AL, "Statin-associated autoimmune myopathy", N Engl J Med, 374, pp.664~669 (2016)
- Lee J, "Statin-induced immune-mediated necrotizing myopathy with anti-HMGCR antibody", Korean J Neuromuscul Disord, 13, pp.64~66 (2021)
- Yung Y, "Statin-naïve paraneoplastic anti-HMGCR myopathy", Korean J Neuromuscul Disord, 13, pp.15~19 (2021)
- Rankin J, "Cerebral vascular accidents in patients over the age of 60. II. Prognosis", Scott Med J, 2, pp.200~215 (1957)
- Lundberg IE, "2017 European League Against Rheumatism", American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups, 2017, pp.76, 1955~1964
- Musset L, "Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies", J Immunol Res, 2014, pp.405956~ (2014)
- Fischer D, "Different early pathogenesis in myotilinopathy compared to primary desminopathy", Neuromuscul Disord, 16, pp.361~367 (2006)
- Jungbluth H, "Magnetic resonance imaging of muscle in congenital myopathies associated with RYR1 mutations", Neuromuscul Disord, 14, pp.785~790 (2004)
- Allenbach Y, "Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin", Medicine(Baltimore), 93, pp.150~157 (2014)
- Watanabe Y, "Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan", Medicine(Baltimore), 94, pp.e416~ (2015)
- Alshehri A, "Myopathy with anti-HMGCR antibodies : perimysium and myofiber pathology", Neurol Neuroimmunol Neuroinflamm, 2, pp.e214~ (2015)
- Kadoya M, "Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy", Neurol Neuroimmunol Neuroinflamm, 3, pp.e290~ (2016)
- Allenbach Y, "High risk of cancer in autoimmune necrotizing myopathies : usefulness of myositis specific antibody", Brain, 139(Pt 8), pp.2131~2135 (2016)
- Mohassel P, "Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy", Neurol Neuroimmunol Neuroinflamm, 6, pp.e523~ (2019)
- Idiculla PS, "Anti-HMGCR myopathy mimicking limb-girdle muscular dystrophy and the response to Rituximab", Clin Neurol Neurosurg, 194, pp.105871~ (2020)
- Drouot L, "Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies", Arthritis Res Ther, 16, pp.R39~ (2014)
- Szczesny P, "Screening for anti-HMGCR antibodies in a large single myositis center reveals infrequent exposure to statins and diversiform presentation of the disease", Front Immunol, 13, pp.866701~ (2022)
- Werner JL, "Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductaseassociated autoimmune myopathy", Arthritis Rheum, 64, pp.4087~4093 (2012)
- Tiniakou E, "More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy", Rheumatology(Oxford), 56, pp.787~794 (2017)
- Ramanathan S, "Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy", Neurol Neuroimmunol Neuroinflamm, 2, pp.e96~ (2015)
- Musset L, "Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies : a history of statins and experience from a large international multi-center study", Autoimmun Rev, 15, pp.983~993 (2016)
- Ashton C, "Treatment and outcomes in necrotising autoimmune myopathy : an Australian perspective", Neuromuscul Disord, 26, pp.734~740 (2016)
- Liang WC, "Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies", Rheumatology(Oxford), 56, pp.287~293 (2017)
- Tansley SL, "The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity", Rheumatology(Oxford), 59, pp.2109~2114 (2020)